Acer Therapeutics Inc. (NASDAQ: ACER) is -19.70% lower on its value in year-to-date trading and has touched a low of $1.08 and a high of $7.25 in the current 52-week trading range. The ACER stock was last observed hovering at around $3.22 in the recent trading session, with the current gains setting it 0.33% off its average median price target of $10.00 for the next 12 months. It is also 64.5% off the consensus price target high of $10.00 offered by 5 analysts, but current levels are -0.85% lower than the price target low of $3.52 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $3.55, the stock is 7.17% and 11.25% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.49 million and changing 10.16% at the moment leaves the stock 7.83% off its SMA200. ACER registered -10.80% loss for a year compared to 6-month loss of -13.21%. The firm has a 50-day simple moving average (SMA 50) of $3.3044 and a 200-day simple moving average (SMA200) of $3.2675.
The stock witnessed a 1.90% gain in the last 1 month and extending the period to 3 months gives it a 69.47%, and is -6.12% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.54% over the week and 11.53% over the month.
Distance from 52-week low is 228.45% and -51.07% from its 52-week high.
Acer Therapeutics Inc. (ACER) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Acer Therapeutics Inc. (ACER) is a “Overweight”. 5 analysts offering their recommendations for the stock have an average rating of 2.60, where 3 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Acer Therapeutics Inc. is expected to release its quarterly report on 08/18/2020 and quarterly earnings per share for the current quarter are estimated at -$0.38.The EPS is expected to shrink by -17.20% this year.
Acer Therapeutics Inc. (ACER) Top Institutional Holders
66 institutions hold shares in Acer Therapeutics Inc. (ACER), with 2.53M shares held by insiders accounting for 24.64% while institutional investors hold 68.91% of the company’s shares. The shares outstanding are 10.10M, and float is at 7.10M with Short Float at 8.15%. Institutions hold 51.93% of the Float.
The top institutional shareholder in the company is Nantahala Capital Management, LLC with over 0.99 million shares valued at $1.97 million. The investor’s holdings represent 9.67% of the ACER Shares outstanding. As of Mar 30, 2020, the second largest holder is Blackrock Inc. with 0.39 million shares valued at $0.78 million to account for 3.80% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 0.17 million shares representing 1.65% and valued at over $0.34 million, while State Street Corporation holds 1.33% of the shares totaling 0.14 million with a market value of $0.27 million.
Acer Therapeutics Inc. (ACER) Insider Activity
A total of 1 insider transactions have happened at Acer Therapeutics Inc. (ACER) in the last six months, with sales accounting for 1 and purchases happening 0 times.
Acer Therapeutics Inc. (ACER): Who are the competitors?
The company’s main competitors (and peers) include Momenta Pharmaceuticals Inc. (MNTA) that is trading 191.39% up over the past 12 months. Novartis AG (NVS) is -3.23% down on the 1-year trading charts. Short interest in the company’s stock has risen 18.88% from the last report on May 14, 2020 to stand at a total of 0.47 million short shares sold with a short interest ratio of 1.55.